Physician profile
Dipa Raval
NPI 1427234442
$881.43
in general payments reported to CMS, 2019-2025
11 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.09 · 2021: $144 · 2023: $230 · 2024: $300 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $209.26 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $157.88 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $113.97 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $107.70 | 2024-2025 | |
| Abbvie INC. | $96.20 | 2023-2024 | |
| Amgen INC. | $74.04 | 2024-2025 | Repatha, Otezla, Repatha |
| Daiichi Sankyo INC. | $58.21 | 2023 | Injectafer |
| Boston Scientific Corporation | $18.73 | 2021 | |
| Lilly USA, LLC | $18.34 | 2024 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $14.01 | 2023 | Shingrix, Arexvy |
| Aytu Biopharma, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipa Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.